Marilu Jurado, MD
Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1245592195
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $711 of the $1,116 with a category attached, or 63.7%. Medtronic accounts for 70.7% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $787, more than ten times the $29 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in FL, where the typical reported total is $3,445.
Across 30 payments — averaging $37.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$789
- Abbott$61
- Insulet Corporation$43
- Lilly USA, LLC$43
- Novo Nordisk$43
- Amneal Pharmaceuticals LLC$37
- plus $99 from 4 others
Across 10 payments — averaging $14,470 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$145K
What the payments were for
- Travel & lodging$39335%
- Food & beverage$71164%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 11 | $789 |
| Abbott | 4 | $61 |
| Insulet Corporation | 2 | $43 |
| Lilly USA, LLC | 3 | $43 |
| Novo Nordisk | 3 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Bayer | 1 | $26 |
| Amgen | 1 | $20 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$418
How this compares
$1,116 in reported general payments places this provider in the 30th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 376 | $524,283 |
| OzempicSemaglutide | 329 | $477,081 |
| TrulicityDulaglutide | 133 | $225,905 |
| JardianceEmpagliflozin | 159 | $211,545 |
| Humulin R U-500Insulin Regular, Human | 11 | $147,957 |
| FarxigaDapagliflozin Propanediol | 82 | $111,461 |
| RybelsusSemaglutide | 40 | $68,324 |
| JanuviaSitagliptin Phosphate | 59 | $63,747 |
| Humalog Kwikpen U-100Insulin Lispro | 115 | $56,387 |
| Tresiba Flextouch U-100Insulin Degludec | 74 | $46,681 |
| Novolog FlexpenInsulin Aspart | 103 | $46,061 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $43,255 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 244 | $34,701 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $24,803 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $20,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $43 | $756,557522 claims |
| Novo NordiskOzempic, Rybelsus | $43 | $545,405369 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $6,050602 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Miami
- Jay SkylerMiami$2.2M
- Eugenio Angueira-SerranoMiami$603K
- Rodolfo GalindoMiami$229K
- Camillo RicordiMiami$128K
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.